Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls

The evolving contribution of hematopoietic progenitor cells to lymphomagenesis

(2012) O. Weigert et al.   BLOOD

Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients

(2012) G. Salles et al.   BLOOD

The B-cell receptor signaling pathway as a therapeutic target in CLL

(2012) J. A. Woyach et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells

(2012) Emma Hamilton et al.   BRITISH JOURNAL OF HAEMATOLOGY

Synergy between PI3K Signaling and MYC in Burkitt Lymphomagenesis

(2012) Sandrine Sander et al.   CANCER CELL

A Missing Link in Genotype-Directed Cancer Therapy

(2012) René Bernards   CELL

Molecular Pathways: Targeting Phosphoinositide 3-Kinase p110-Delta in Chronic Lymphocytic Leukemia

(2012) S. E. M. Herman et al.   CLINICAL CANCER RESEARCH

Obinutuzumab (GA101) – a different anti-CD20 antibody with great expectations

(2012) Tim M Illidge   EXPERT OPINION ON BIOLOGICAL THERAPY

Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Subtypes

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the B-Cell Lymphoma/Leukemia 2 Family in Cancer

(2012) Matthew S. Davids et al.   JOURNAL OF CLINICAL ONCOLOGY

Alemtuzumab in Combination With Methylprednisolone Is a Highly Effective Induction Regimen for Patients With Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial

(2012) Andrew R. Pettitt et al.   JOURNAL OF CLINICAL ONCOLOGY

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics

(2012) Roland Schmitz et al.   NATURE

BRAF Inhibition in Refractory Hairy-Cell Leukemia

(2012) Sascha Dietrich et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice

(2012) C. Vicente-Duenas et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101

(2011) M. Jak et al.   BLOOD

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

(2011) L. Xi et al.   BLOOD

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

Self-Renewing Hematopoietic Stem Cell Is the Primary Target in Pathogenesis of Human Chronic Lymphocytic Leukemia

(2011) Yoshikane Kikushige et al.   CANCER CELL

Nilotinib and MEK Inhibitors Induce Synthetic Lethality through Paradoxical Activation of RAF in Drug-Resistant Chronic Myeloid Leukemia

(2011) Leisl M. Packer et al.   CANCER CELL

Phase II Study of Dasatinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

(2011) P. C. Amrein et al.   CLINICAL CANCER RESEARCH

miR-125b and miR-155 Contribute to BCL2 Repression and Proliferation in Response to CD40 Ligand (CD154) in Human Leukemic B-cells

(2011) Shaun Willimott et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

From Mitochondrial Biology to Magic Bullet: Navitoclax Disarms BCL-2 in Chronic Lymphocytic Leukemia

(2011) Loren D. Walensky   JOURNAL OF CLINICAL ONCOLOGY

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

(2011) Andrew W. Roberts et al.   JOURNAL OF CLINICAL ONCOLOGY

SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies

(2011) S Hart et al.   LEUKEMIA

Intravenous gammaglobulin suppresses inflammation through a novel TH2 pathway

(2011) Robert M. Anthony et al.   NATURE

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

BRAFMutations in Hairy-Cell Leukemia

(2011) Enrico Tiacci et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity

(2010) E. Mossner et al.   BLOOD

The DLEU2/miR-15a/16-1 Cluster Controls B Cell Proliferation and Its Deletion Leads to Chronic Lymphocytic Leukemia

(2010) Ulf Klein et al.   CANCER CELL

The expression of Bcl-2 by proliferating cells varies in different categories of B-cell lymphoma

(2010) Noraidah Masir et al.   HISTOPATHOLOGY

Tonic BCR signaling represses receptor editing via Raf- and calcium-dependent signaling pathways

(2010) Laura B. Ramsey et al.   IMMUNOLOGY LETTERS

BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy

(2010) Leandro C. Cerchietti et al.   JOURNAL OF CLINICAL INVESTIGATION

Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia

(2010) William G. Wierda et al.   JOURNAL OF CLINICAL ONCOLOGY

Is Anticancer Drug Development Heading in the Right Direction?

(2009) Trevor W. Hambley   CANCER RESEARCH

Enhanced Fas-associated death domain recruitment by histone deacetylase inhibitors is critical for the sensitization of chronic lymphocytic leukemia cells to TRAIL-induced apoptosis

(2009) S. Inoue et al.   MOLECULAR CANCER THERAPEUTICS

More is less—combining targeted therapies in metastatic colorectal cancer

(2009) Cornelis J. A. Punt et al.   Nature Reviews Clinical Oncology

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia

(2008) M. Vogler et al.   BLOOD

Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival

(2008) N. A. Johnson et al.   BLOOD

Do molecularly targeted agents in oncology have reduced attrition rates?

(2008) Ian Walker et al.   NATURE REVIEWS DRUG DISCOVERY